Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Growth hormone therapy.

L Shulman1, J L Miller, L I Rose

  • 1Division of Endocrinology-Metabolism, Hahnemann University School of Medicine, Philadelphia, Pennsylvania.

American Family Physician
|May 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prenatal diagnosis of umbilical-portal-systemic venous shunt associated with gestational alloimmune liver disease.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2025
Same author

Resolution of selective fetal growth restriction after laser surgery for twin-to-twin transfusion syndrome can be predicted by predisease growth discordance.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2025
Same author

Standardized approach to ultrasound-guided balloon puncture for reversal of tracheal occlusion in congenital diaphragmatic hernia.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2024
Same author

MoMo pregnancies, Mo problems: monochorionic monoamniotic triplet pregnancy with conjoined twins.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2024
Same author

Lymphoma.

The Journal of comparative medicine and veterinary archives·2022
Same author

Patient-matched fetal simulator for fetoscopic myelomeningocele closure.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2022
Same journal

For Post-stent Patients With Atherosclerotic Coronary Vascular Disease Who Are Taking an Anticoagulant, Adding Aspirin Worsens Outcomes.

American family physician·2026
Same journal

Nausea and Vomiting During Pregnancy.

American family physician·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management.

American family physician·2026
Same journal

Aerobic Exercise Is the Better Exercise Modality for Knee Osteoarthritis.

American family physician·2026
Same journal

Overscreening Leads to Overdiagnosis of MASLD.

American family physician·2026
Same journal

Type 2 Diabetes: Outpatient Insulin Management.

American family physician·2026
See all related articles

Synthetic growth hormone, available since 1985, offers a safe alternative to pituitary-derived hormone for treating growth deficiencies. It effectively promotes normal skeletal and muscular development in patients with various growth disorders.

Area of Science:

  • Endocrinology
  • Biotechnology
  • Medical Science

Background:

  • Human pituitary growth hormone was historically scarce and posed a risk of transmitting Creutzfeldt-Jakob disease.
  • Use of pituitary-derived growth hormone was discontinued in 1984 due to safety concerns.

Purpose of the Study:

  • To evaluate the efficacy and safety of synthetic growth hormone in treating growth disorders.
  • To highlight the advantages of recombinant DNA technology in hormone production.

Main Methods:

  • Utilized synthetic growth hormone produced via recombinant DNA technology.
  • Administered growth hormone for treatment of pituitary deficiency syndromes, Turner's syndrome, and constitutional growth delay.

Main Results:

Related Experiment Videos

  • Synthetic growth hormone effectively induces normal skeletal and muscular development when administered early.
  • Successful growth augmentation was observed in patients with Turner's syndrome and constitutional growth delay.
  • Side effects were generally not serious, with antibody development in approximately 30% of patients.

    • Conclusions:

    • Recombinant DNA technology has provided a safe and effective alternative to human pituitary growth hormone.
    • Synthetic growth hormone is a valuable therapeutic agent for specific growth-related conditions.
    • Early intervention with growth hormone is crucial for optimal developmental outcomes.